📊 Backtest📒 Journal Updated 13/08/2026
← ⚡ Catalyst
📐 Simulate Position
STALE?Report written 9 days ago · at $24.45entry levels may be stale — re-check before acting

ZYME

SpeculativeSMALL CAP
Zymeworks Inc. · NASDAQ · Healthcare / Biotechnology (Oncology — Bispecific Antibodies)
$24.45
▲ 2.30%
MCap $1.75B
Up 2.3% intraday, still well off the 52-week high of $29.75, recovering from the Aug 6 Q2 earnings miss (EPS -$0.62 vs -$0.37 est., revenue $4.6M vs $19.1M est.) as the market looks past the small BTC commercial base toward the Aug 25 GEA-label PDUFA decision.
BusinessBiotech · Bispecific antibody platform (zanidatamab/Ziihera) partnered with Jazz Pharmaceuticals — milestone + royalty stream on an oncology franchise expanding from 2L biliary tract cancer into 1L gastroesophageal adenocarcinoma
Thesis

Zymeworks' zanidatamab (marketed as Ziihera, partnered with Jazz Pharmaceuticals) already has FDA approval in 2nd-line HER2+ biliary tract cancer since Nov 2024. The Aug 25, 2026 PDUFA date is for a supplemental BLA adding first-line HER2+ gastroesophageal adenocarcinoma (GEA) — a much larger population — backed by a positive Phase 3 (HERIZON-GEA-01: median PFS 12.4 vs 8.1 months, HR 0.63, p<.0001) and Priority Review status. Approval unlocks a $250M US milestone (of $440M total) plus a materially bigger royalty base, but the Q2 revenue miss shows the current BTC business alone is still thin, and the payout flows through Jazz as milestones/royalties, not full commercial upside.

📝 Primary Verdict · Core Holding
SPECULATIVESpeculative

SPECULATIVE (Buy the binary) — Priority Review + a statistically strong Phase 3 (HR 0.63, p<.0001) lowers approval risk versus a typical first-in-class biotech bet, but the Jazz-partnered royalty structure caps direct upside and a CRL is never zero-probability. Small, sized-for-binary-risk position into Aug 25.

76
score / 100 ⓘ
⚡ Catalyst
💊 Zanidatamab 1L GEA PDUFA Decision2 WEEKS

FDA target action date for the sBLA (filed by partner Jazz Pharmaceuticals) adding first-line HER2+ gastroesophageal adenocarcinoma to the label. Priority Review was granted on positive Phase 3 HERIZON-GEA-01 data (median PFS 12.4mo vs 8.1mo, HR 0.63, p<.0001; median OS >2 years). Approval unlocks a $250M US regulatory milestone (part of $440M total) plus a much larger addressable population than the existing 2L BTC indication.

Aug 25, 2026
📊 Q2 2026 Earnings (reported)PASSED

Reported Aug 6, 2026: EPS -$0.62 missed estimate by $0.25, revenue $4.6M vs $19.1M consensus — a real miss. Despite that, Citi raised its target to $37 (from $35) and kept Buy, reading the miss as noise against the PDUFA setup.

Aug 6, 2026
🎯 Entry Point
Entry 1
$24.45
Current price, pre-PDUFANow
Entry 2PREFERRED
$20–22
Pullback zone if biotech risk appetite softens (e.g. hot CPI Aug 12) before the Aug 25 decisionIf dips
Entry 3
$16.00
Deep dip toward the 52-week low zone — would need a broad biotech selloff or a negative pre-PDUFA signalDeep dip only
✅ Take Profit
TP1
Base — approval lands as expected, muted reaction (similar pattern to the Nov 2024 BTC approval)
$27.87
+14%
TP2
Bull — approval confirmed, 1L GEA label meaningfully expands the addressable market, hits Citi's post-earnings target
$37
+51.3%
TP3 🌙
Moon — approval + Street re-rates toward the high end of the Strong Buy range as GEA royalty economics get modeled in
$46.46
+90%
🔴 Stop Loss
Tight Stop
Pre-PDUFA technical stop — a break below this level suggests the market is pricing in real rejection risk ahead of Aug 25
$22
-10%
Hard Stop
Deep breach — would reflect a Complete Response Letter (CRL) or a safety signal surfacing before the decision
$19.56
-20%
Risk / Reward
Entry 1 to hard stop vs TP2 (Bull case)
2.6 : 1
⚠ Binary PDUFA event — a technical stop is only a partial hedge; size the position for the Bear-case CRL scenario, not just the stop distance
📅 Estimate Date
Zanidatamab 1L GEA PDUFA
FDA target action date, Priority Review — positive Phase 3 data (HR 0.63, p<.0001) already public
Aug 25, 2026
high approval probability, not certain
Q3 2026 Earnings
Next scheduled financial update, after the PDUFA decision
Nov 2026
n/a
📈 Stock Timeline
1 snapshot · Aug 10
First snapshot — check back next week
Score
62
Aug 10
TP2 Target
$37
Aug 10
Rank
#27
Aug 10
📈 Possible Up % — Scenario Spread
Bear
-35%
$15.89
Base
+14%
$27.87
Bull
+51.3%
$37
Moon
+90%
$46.46
← downsideupside →
🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed held at 3.50-3.75% on Jul 29, 2026, but 3 of 12 officials dissented in favor of a hike — the most hawkish dissent split since 2016. Next FOMC is Sep 15-16, 2026, after this PDUFA. CPI prints Aug 12, 2026, sits directly between this report and the Aug 25 decision and could move risk appetite for small-cap biotech financing broadly.
Inflation
Core PCE still running 3.3% YoY, above the Fed's 2% target — a hot Aug 12 CPI could trigger a broad risk-off move in small/micro-cap biotech (rate-sensitive sector via financing costs) independent of ZYME's own binary outcome.
Sector Impact
Small-cap clinical/commercial biotech is more sensitive to risk-appetite swings than idiosyncratic FDA-driven names would suggest — a hawkish CPI surprise before Aug 25 could compress the stock's pre-PDUFA run-up regardless of the underlying approval odds.
Summary
MEDIUM — the approval decision itself is idiosyncratic and largely macro-independent, but the CPI print (Aug 12) lands squarely in the run-up window and a hawkish surprise could dampen the sector-wide biotech risk appetite this specific trade depends on for its pre-catalyst positioning.
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Citi
Buy$37+51%
Wall Street Consensus (Strong Buy)
Strong Buy$44.5+82%
current price $24.45
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

ZYME⚡ MixedNov 2024
-7.97%
in 1 day
Ziihera (zanidatamab) accelerated approval — 2L HER2+ biliary tract cancer
Same drug's first FDA approval — the stock fell ~8% the day it was announced (alongside Q4 results) because accelerated approval was already largely expected. Direct precedent for why the Aug 25 GEA sBLA approval may not produce a large pop even if it clears.
OMER✅ GoodAug 2026
+8%
in 1 day
Yartemlea first-in-class FDA approval (rare transplant complication)
Recent same-window example: even a genuine first-of-its-kind approval only produced a modest +8% premarket pop — approvals well-telegraphed by Priority Review status tend to already be partly priced in before the decision date.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-15% / -25%) only when trading the earnings spot — not for the core holding (use the -10% / -20% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
+20% to +40% is the general Priority-Review pattern; ZYME's own run has been choppier given the earnings miss4–8 weeks before PDUFA (since late June/early July 2026), interrupted by the Aug 6 earnings miss

Priority-Review PDUFA setups typically see a 4-8 week pre-decision run-up as positioning builds ahead of the binary. ZYME has partly followed this pattern off its 52-week low ($10.93), but the Aug 6 earnings miss interrupted the run-up, so less is 'priced in' heading into Aug 25 than a clean Priority Review setup would normally show.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +15%
range: +8% to +25%· Nov 2024 (ZYME BTC approval) / Aug 2026 (OMER)
Approval on an already-partnered, already-marketed drug tends toward the muted end of the typical 30-200% first-approval range, since much is already priced in. ZYME's own 2024 BTC approval barely moved the stock (-8% same-day, alongside an earnings release); Omeros' first-in-class approval in Aug 2026 added only +8% premarket.
❌ Catalyst Missavg -30%
range: -20% to -40%· N/A — general oncology PDUFA/CRL pattern, no ZYME-specific prior case
No direct ZYME-specific CRL precedent exists to cite — this is the general pattern for Priority-Review oncology sBLAs with strong Phase 3 data that still receive a CRL or restrictive label; the surprise factor amplifies the reaction versus a name where rejection was already expected.
💼Spot Position Sizing
How the recommended % is derived
3%
of portfolio

Binary PDUFA event on a $1.75B-cap name with real CRL tail risk — even with Priority Review and strong Phase 3 data, this is sized like a speculative/ค่าขนม position, not a core holding

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-15%($20.78)
A break below $20-21 before Aug 25 signals the market is pricing in real rejection risk — exit before the binary if this level breaks
After Catalyst (Bad Result)-25%
If approved but the stock still sells off past -25% (e.g. a narrow/restricted label), the 'clean broad approval' thesis has failed even though the drug technically cleared
📎 Sources

Generated 2026-08-10 · Not financial advice